[1] Xu R, Barg F K, Emmett E A, et al.Association between mesothelioma and non-occupational asbestos exposure:systematic review and meta-analysis[J].Environ Health, 2018,17(1):90.
[2] Abdel-Rahman O.Global trends in mortality from malignant mesothelioma:Analysis of WHO mortality database (1994-2013)[J].Clin Respir J, 2018, 12(6):2090-2100.
[3] Beebe-Dimmer J L, Fryzek J P, Yee C L, et al.Mesothelioma in the United States:a surveillance, epidemiology, and end results (SEER)-medicare investigation of treatment patterns and overall survival[J].Clin Epidemiol, 2016, 8:743-750.
[4] Verma V, Sleightholm R L, Rusthoven C G, et al.Malignant peritoneal mesothelioma:national practice patterns, outcomes, and predictors of survival[J].Ann Surg Oncol, 2018, 25(7):2018-2026.
[5] Tabrizian P, Franssen B, Jibara G, et al.Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma[J].J Surg Oncol, 2014, 110(7):786-790.
[6] Raza A, Huang W C, Takabe K.Advances in the management of peritoneal mesothelioma[J].World J Gastroenterol, 2014, 20(33):11700-11712.
[7] Del Gobbo A, Fiori S, Gaudioso G, et al.Synchronous pleural and peritoneal malignant mesothelioma:a case report and review of literature[J].Int J Clin Exp Pathol, 2014, 7(5):2484-2489.
[8] Chua T C, Chong C H, Morris D L.Peritoneal mesothelioma current status and future directions[J].Surg Oncol Clin N Am, 2012, 21(4):635-643.
[9] Rice D, Rusch V, Pass H, et al.Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma:a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group[J].J Thorac Oncol, 2011, 6(8):1304-1312.
[10] Kim S, Bull D A, Garland L, et al.Is there a role for cancer-directed surgery in early-stage sarcomatoid or biphasic mesothelioma?[J].Ann Thorac Surg, 2019, 107(1):194-201.
[11] Sugarbaker D J, Norberto J J.Multimodality management of malignant pleural mesothelioma[J].Chest, 1998, 78(3):S503-S504.
[12] Rusch V W, Rosenzweig K, Venkatraman E, et al.A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma[J].J Thorac Cardiovasc Surg, 2001, 122(4):788-795.
[13] Migliore M, Calvo D, Criscione A, et al.Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma:initial experience[J].Future Oncol, 2015, 11(24s):19-22.
[14] Jin S, Cao S, Cao J, et al.Predictive factors analysis for malignant peritoneal mesothelioma[J].J Gastrointest Surg, 2015, 19(2):319-326.
[15] Kim J, Bhagwandin S, Labow D M.Malignant peritoneal mesothelioma:a review[J].Ann Transl Med, 2017, 5(11):236.
[16] Yan T D, Deraco M, Baratti D, et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma:multi-institutional experience[J].J Clin Oncol, 2009, 27(36):6237-6342.
[17] Signorelli D, Macerelli M, Proto C, et al.Systemic approach to malignant pleural mesothelioma:what news of chemotherapy, targeted agents and immunotherapy?[J].Tumori, 2016,102(1):18-30. |
